Special Issue

Fighting SARS-CoV-2 and Related Viruses

Message from the Guest Editors

Since the worldwide outbreak of COVID-19, the entire scientific community has mobilized to find ways to combat SARS-CoV-2, the coronavirus responsible for the disease. Studies began with assays involving repurposable drugs: since then, there have been thousands of clinical trials. Molecular modeling methods and artificial intelligence enabled the selection of numerous potentially effective agents. Screening of libraries of small molecules, more complex biomolecules, or extracts from natural sources remains the focus of many studies, whereas vaccines have emerged as the most widely employed weapon in response to the epidemic. This Topical Collection will cover all aspects involved in the fight against SARS-CoV-2 and related viruses. Reviews and research articles are preferred; however, hypotheses, opinions, and reports on clinical trials will also be considered.

Guest Editors

Dr. Jean Jacques Vanden Eynde

Formerly Head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium

Dr. Annie Mayence

Formerly Professor, Haute Ecole Provinciale de Hainaut-Condorcet, 7330 Saint-Ghislain, Belgium

Deadline for manuscript submissions

closed (30 September 2025)



Drugs and Drug Candidates

an Open Access Journal by MDPI



mdpi.com/si/131778

Drugs and Drug Candidates Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 ddc@mdpi.com

mdpi.com/journal/ddc





Drugs and Drug Candidates

an Open Access Journal by MDPI





About the Journal

Message from the Editor-in-Chief

Drugs and Drug Candidates is an open access initiative of MDPI (Basel, Switzerland). Do you wish to share your knowledge on marketed or newly approved drugs for human or veterinary use? Do you wish to disseminate your recent results on the search for novel promising drug candidates? Our journal, animated by a young and dynamic team, is the ideal platform! Your submission, carefully followed by an academic editor, will be peerreviewed by experts in the field of the work and a first decision will be notified within no more than two weeks. Involved in drug design, drug synthesis, drug evaluation, or drug market, Drugs and Drug Candidates is of worthy recognition and value.

I look forward to handling your contributions in the very near future. Should you need any information, do not hesitate to contact us.

Editor-in-Chief

Dr. Jean Jacques Vanden Eynde

Formerly Head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15 days after submission; acceptance to publication is undertaken in 4.7 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.